Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2010 / Cilt: 44 - Sayı: 2

Efficacy of pimecrolimus 1% cream in various clinical forms of atopic dermatitis

Atopik dermatit klinik tipleri arasında %1 pimekrolimus krem tedavisinin etkinliğinin araştırılması

Pages
83–87
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The difference between the SCORADs before and after the treatment was found to be statistically significant (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: Atopic dermatitis shows some different clinical appearances.The main aim of this experimental study is to compare the efficacy of pimecrolimus among these clinical subgoups of atopic dermatitis.
📊
Key Findings & Data:Material and Method: A total of 70 patients, 50 male and 20 female, aged between 2-38 years were included in the study.
💡
Conclusion & Impact:The difference between the SCORADs before and after the treatment was found to be statistically significant (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and Design: Atopic dermatitis shows some different clinical appearances.The main aim of this experimental study is to compare the efficacy of pimecrolimus among these clinical subgoups of atopic dermatitis. Material and Method: A total of 70 patients, 50 male and 20 female, aged between 2-38 years were included in the study. Twenty-two patients (%31.4) were pediatric (2-10 years). Patients were investigated in regard to high levels of total IgE, airway allergy, positive skin prick test and triggering allergens. Patients were classified as: mixed, pure intrinsic and pure extrinsic according to Wüthrich classification. Pimecrolimus 1% cream was applied to the patients twice daily for 6 weeks and patients were evaluated with SCORAD index before and after treatment. Results: FAs a result, 58.6% of the patients (n=41) had a successful therapy with pimecrolimus while 4.3% (n=3) had partially successful. Thirty-five patients achieved full remission. The difference between the SCORADs before and after the treatment was found to be statistically significant (p

Özet

Amaç: Atopik dermatit bilindiği gibi farklı klinik tiplerde karşımıza çıkar. Bu deneysel çalışmanın temel amacı, atopik dermatitin bu tipleri arasında pimekrolimusun etkinliğini karşılaştırmaktır. Gereç ve Yöntem: Çalışmaya 2-38 yaşları arasında, 50’si erkek, 20’si kadın, toplam 70 hasta alındı. Hastaların 22’si (%31,4) çocuktu (2-10 yaş). Hastalarda, solunum yolu allerjisi, total IgE yüksekliği, deri “prick” test pozitifliği ve tetikleyici allerjenler araştırıldı. Hastalar Wüthrich sınıflamasına göre, “mikst”, “pür intrinsik” ve “pür ekstrinsik” olarak sınıflandırıldı. Hastalara 6 hafta boyunca günde iki kez %1 pimekrolimus krem tedavisi uygulandı ve hastalar SCORAD indeksi kullanılarak değerlendirildi. Bulgular: Sonuç olarak hastaların %58,6’sında (n=41) tedavi başarılı, %4,3’ünde (n=3) tedavi kısmen başarılı, %37,1’inde (n=26) tedavi başarısız bulundu. 35 hastada tam remisyon elde edildi. Tedavi öncesi ve sonrasındaki SCORAD değerleri arasındaki fark, istatistiksel olarak anlamlı bulundu (p

🔖

Cite This Article

DOĞAN, B., KARABUDAK, Ö., İKİZLER, E., KARABACAK, E. (2022). Efficacy of pimecrolimus 1% cream in various clinical forms of atopic dermatitis. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 44 - Sayı: 2, 83–87. https://ajindex.com/articles/622046

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Falco OB, Plewig G, Wolff HH, Winkelman RK: Dermatology. 2nd edition. Berlin, Springer, 2000;499-509
  2. Leung DY: Pathogenesis of Atopic Dermatitis. J Allergy Clin Immunol 1999;99-108
  3. Akdis CA, Akdis M: Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin Exp Allergy 2003;33:1618-21
  4. Hanifin JM: Atopiform Dermatitis:do we need another confusing name for atopic dermatitis? Br J Dermatol 2002;147:430-32
  5. Ohman S, Johansson SGO: Immunoglobulins in atopic dermatitis. Acta Derm Venerol (Stockh) 1974;54:193-202
  6. Jones HE, Inouye JC, McGerity JL, Lewis CW: Atopic disease and serum immunoglobulin-E. Br J Dermatol 1975;92:17-25
  7. Wüthrich B, Schmid-Grendelmeier P: Definition and diagnosis of intrinsic versus extrinsic atopic dermatitis. Atopic dermatitis. Eds. Bieber T., Leung DYM. New York, Marcel Dekker, 2002; 1-20
  8. Bieber T: Atopic Dermatitis. The New England Journal Of Medicine 2008;358:1483-94
  9. Chang MW: Review of atopic dermatitis. Journal Watch Dermatology 2008; 402
  10. Levy ML: Atopic dermatitis: understanding the disease and its management. Curr Med Res Opin 2007;23:3091-103
  11. Buys LM: Treatment options for atopic dermatitis. Am Fam Physician 2007;75:523-8
  12. Lewis Jones S, Mugglestone MA: Guideline Development Group: Management of atopic eczema in children aged up to 12 years: summary of NICE guidance. BMJ 2007;335:1263-4
  13. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index (consensus report of the European Task Force on Atopic Dermatitis) Dermatology 1993;186:23-31
  14. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005; 330:516
  15. Herd RM: The morbidity and cost of atopic dermatitis. Atopic dermatitis. Ed. Williams HC. Cambridge, Cambridge University Press, 2000: 85-95
  16. Meurer M, Lübbe J, Kapp A, Schneider D: The role of pimecrolimus cream 1%(Elidel) in managing adult atopic eczema. Dermatology 2007;215:18-26
  17. Abeck D, Strom K: Optimal management of atopic dermatitis. Am J Clin Dermatol 2000;1:41-6
  18. Hepburn D, Yohn JJ, Weston WL: Topical steroid treatment in infants, children and adolescents. Adv Dermatol 1994;9:225-55
  19. Charman CR, Morris AD, Williams HC: Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142:931-6
  20. Lapsl